Simply stated, without a dramatic increase in R&D productivity, today’s pharmaceutical industry cannot sustain sufficient innovation to replace the loss of revenue due to patent expirations for successful products (Nature Reviews, March 2010). In addressing this crisis, next-generation approaches to clinical development have received disproportionate attention within industry, academia and regulatory agencies (1). At Evince, we are committed to substantially reducing the cost by increasing productivity in drug discovery via an artificial intelligence based in silico platform. A careful analysis reveals that the capitalized cost of discovery and preclinical development is 46% of total R&D costs, compared with 54% for clinical development (Nature Reviews, March 2010). It is counterintuitive that the cost of discovery and preclinical development should be such a large percentage of the total cost.
Skipping Discovery Will Kill Your Deals
It’s no secret by now that your sales process needs to be a defined set of steps that bring a prospect from infancy to…